Bmc Cancer

BackgroundAssessment of the clinical significance of unclassified variants (UVs) identified in BRCA1 and BRCA2 is very important for genetic counselling. The analysis of co-segregation of the variant with the disease in families is a powerful tool for the classification of these variants. Statistical methods have been described in literature but these methods are not always easy to apply in a diagnostic setting.MethodsWe have developed an easy to use method which calculates the likelihood ratio (LR) of an UV being deleterious, with penetrance as a function of age of onset, thereby avoiding the use of liability classes. The application of this algorithm is publicly available http://www.msbi.nl/cosegregation. It can easily be used in a diagnostic setting since it requires only information on gender, genotype, present age and/or age of onset for breast and/or ovarian cancer.ResultsWe have used the algorithm to calculate the likelihood ratio in favour of causality for 3 UVs in BRCA1 (p.M18T, p.S1655F and p.R1699Q) and 5 in BRCA2 (p.E462G p.Y2660D, p.R2784Q, p.R3052W and p.R3052Q). Likelihood ratios varied from 0.097 (BRCA2, p.E462G) to 230.69 (BRCA2, p.Y2660D). Typing distantly related individuals with extreme phenotypes (i.e. very early onset cancer or old healthy individuals) are most informative and give the strongest likelihood ratios for or against causality.ConclusionAlthough co-segregation analysis on itself is in most cases insufficient to prove pathogenicity of an UV, this method simplifies the use of co-segregation as one of the key features in a multifactorial approach considerably.

[1]  P. Devilee,et al.  Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines , 2005, European Journal of Human Genetics.

[2]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[3]  M. King,et al.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.

[4]  W. Otten,et al.  The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life , 2008, Psycho-oncology.

[5]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[6]  W. E. Hoogendoorn,et al.  Modeling familial clustered breast cancer using published data. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  P. Devilee,et al.  A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history , 2009, Breast Cancer Research.

[8]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[9]  Douglas F Easton,et al.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model , 2008, Human mutation.

[10]  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Skolnick,et al.  Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. Commentaries , 1996 .

[12]  Andrej Sali,et al.  Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. , 2007, Cancer research.

[13]  Douglas F Easton,et al.  A full-likelihood method for the evaluation of causality of sequence variants from family data. , 2003, American journal of human genetics.

[14]  J. Hopper,et al.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. , 2006, Cancer research.

[15]  H. Putter,et al.  Score test for detecting linkage to complex traits in selected samples , 2004, Genetic epidemiology.

[16]  Kiley J. Johnson,et al.  Functional assays for classification of BRCA2 variants of uncertain significance. , 2008, Cancer research.

[17]  G. Parmigiani,et al.  Missense mutations in disease genes: a Bayesian approach to evaluate causality. , 1998, American journal of human genetics.

[18]  J. Benítez,et al.  Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information , 2007, Human mutation.

[19]  R. Elston,et al.  A general model for the genetic analysis of pedigree data. , 1971, Human heredity.

[20]  S. Antonarakis,et al.  Corrigendum: Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2002, Human mutation.

[21]  Peter Devilee,et al.  Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice‐site prediction programs , 2009, Human mutation.